The University of Southampton
University of Southampton Institutional Repository

Patient-reported real-world experience of risankizumab on-body device (OBD) for the treatment of Crohn’s disease in the UK (COMMODUS)

Patient-reported real-world experience of risankizumab on-body device (OBD) for the treatment of Crohn’s disease in the UK (COMMODUS)
Patient-reported real-world experience of risankizumab on-body device (OBD) for the treatment of Crohn’s disease in the UK (COMMODUS)

Objective: to evaluate real-world patient-reported experience with subcutaneous (SC) risankizumab administered by on-body device (OBD) in patients with Crohn’s disease (CD). 

Methods: uncontrolled observational cross-sectional study in five UK units between October 2023 and May 2024. Patients who had received maintenance risankizumab via SC injection of four pre-filled syringes (PFS) self-administered in hospital were switched to OBD self-injection. Self-Injection Assessment Questionnaires (SIAQ) were completed pre- and post-first OBD use. The primary end-point was “Overall, how satisfied are you with your current way of taking your medication (self-injection)?” from post-injection SIAQ. Baseline patient data were collected retrospectively from medical records. 

Results: the study recruited 50 patients with moderate-to-severe CD, 48 completed the study. Most (81%) were satisfied/very satisfied with self-injection using OBD vs only 54% with PFS. Satisfaction with the OBD was highest with home use (90% vs 65%). Confidence was high with the OBD; numerically higher rates of patients were confident in giving themselves an injection in the right way (83% vs 64%), in a clean and sterile way (90% vs 74%) and safely (85% vs 72%) post-OBD than before using OBD. Self-injection using the OBD was reported as easy by 92% and convenient by 83% of participants. Most participants reported that they would continue to use the OBD (82%) and be confident to self-inject at home (81%). The OBD was well tolerated.

Conclusion: the OBD provides a safe, easy to use and convenient way to self-administer risankizumab at home using one injection with improved satisfaction and confidence vs self-administration of four PFS in hospital.

Crohn’s disease, Risankizumab, SIAQ, on-body injector, patient reported outcomes, patient satisfaction
0300-7995
829-839
Jaulim, Adil
581f8620-a588-4740-b84f-a322ecae6028
Stanton, Anna
47e71007-1785-4ef8-82a8-a4f79c0860df
Tripoli, Sherill
b6767b45-69cc-4108-91d6-c0dbf821208f
Ibarra, Ana
3544485b-d72b-4589-b64b-e998560b3464
Young, David
f4b655b7-77bb-428c-a114-ea87ab534cd6
Doona, Mary
3a412500-af9f-498d-8f95-ec541311701f
Cummings, Fraser
d1fea617-b125-4129-89d1-1bfb6d8d2dfe
Speight, Ally
cbacf5f9-54ca-49df-8b8d-e2a8844798bc
Din, Shahida
8868bb63-5739-43b9-a3cc-cfea1dddac89
Lindsay, James O.
8801b506-0b55-43b0-a7dd-c898c8687330
Horsfall, Rachel
41cda9d0-b0c7-4bce-bb5c-af094914cc99
Sephton, Mark
fecf8f55-05e9-4211-a775-74a9edeb9048
Samaan, Mark A.
b3f40a50-dee0-439f-88e5-6e94830d632c
Jaulim, Adil
581f8620-a588-4740-b84f-a322ecae6028
Stanton, Anna
47e71007-1785-4ef8-82a8-a4f79c0860df
Tripoli, Sherill
b6767b45-69cc-4108-91d6-c0dbf821208f
Ibarra, Ana
3544485b-d72b-4589-b64b-e998560b3464
Young, David
f4b655b7-77bb-428c-a114-ea87ab534cd6
Doona, Mary
3a412500-af9f-498d-8f95-ec541311701f
Cummings, Fraser
d1fea617-b125-4129-89d1-1bfb6d8d2dfe
Speight, Ally
cbacf5f9-54ca-49df-8b8d-e2a8844798bc
Din, Shahida
8868bb63-5739-43b9-a3cc-cfea1dddac89
Lindsay, James O.
8801b506-0b55-43b0-a7dd-c898c8687330
Horsfall, Rachel
41cda9d0-b0c7-4bce-bb5c-af094914cc99
Sephton, Mark
fecf8f55-05e9-4211-a775-74a9edeb9048
Samaan, Mark A.
b3f40a50-dee0-439f-88e5-6e94830d632c

Jaulim, Adil, Stanton, Anna, Tripoli, Sherill, Ibarra, Ana, Young, David, Doona, Mary, Cummings, Fraser, Speight, Ally, Din, Shahida, Lindsay, James O., Horsfall, Rachel, Sephton, Mark and Samaan, Mark A. (2025) Patient-reported real-world experience of risankizumab on-body device (OBD) for the treatment of Crohn’s disease in the UK (COMMODUS). Current Medical Research and Opinion, 41 (5), 829-839. (doi:10.1080/03007995.2025.2506808).

Record type: Article

Abstract

Objective: to evaluate real-world patient-reported experience with subcutaneous (SC) risankizumab administered by on-body device (OBD) in patients with Crohn’s disease (CD). 

Methods: uncontrolled observational cross-sectional study in five UK units between October 2023 and May 2024. Patients who had received maintenance risankizumab via SC injection of four pre-filled syringes (PFS) self-administered in hospital were switched to OBD self-injection. Self-Injection Assessment Questionnaires (SIAQ) were completed pre- and post-first OBD use. The primary end-point was “Overall, how satisfied are you with your current way of taking your medication (self-injection)?” from post-injection SIAQ. Baseline patient data were collected retrospectively from medical records. 

Results: the study recruited 50 patients with moderate-to-severe CD, 48 completed the study. Most (81%) were satisfied/very satisfied with self-injection using OBD vs only 54% with PFS. Satisfaction with the OBD was highest with home use (90% vs 65%). Confidence was high with the OBD; numerically higher rates of patients were confident in giving themselves an injection in the right way (83% vs 64%), in a clean and sterile way (90% vs 74%) and safely (85% vs 72%) post-OBD than before using OBD. Self-injection using the OBD was reported as easy by 92% and convenient by 83% of participants. Most participants reported that they would continue to use the OBD (82%) and be confident to self-inject at home (81%). The OBD was well tolerated.

Conclusion: the OBD provides a safe, easy to use and convenient way to self-administer risankizumab at home using one injection with improved satisfaction and confidence vs self-administration of four PFS in hospital.

Text
Patient-reported real-world experience of risankizumab on-body device OBD for the treatment of Crohn s disease in the UK COMMODUS - Version of Record
Download (1MB)

More information

Accepted/In Press date: 12 May 2025
e-pub ahead of print date: 23 May 2025
Keywords: Crohn’s disease, Risankizumab, SIAQ, on-body injector, patient reported outcomes, patient satisfaction

Identifiers

Local EPrints ID: 503469
URI: http://eprints.soton.ac.uk/id/eprint/503469
ISSN: 0300-7995
PURE UUID: abcda88b-8a27-4c8d-be57-0ec7640be0a9
ORCID for David Young: ORCID iD orcid.org/0000-0003-0102-5739

Catalogue record

Date deposited: 01 Aug 2025 16:45
Last modified: 22 Aug 2025 02:34

Export record

Altmetrics

Contributors

Author: Adil Jaulim
Author: Anna Stanton
Author: Sherill Tripoli
Author: Ana Ibarra
Author: David Young ORCID iD
Author: Mary Doona
Author: Fraser Cummings
Author: Ally Speight
Author: Shahida Din
Author: James O. Lindsay
Author: Rachel Horsfall
Author: Mark Sephton
Author: Mark A. Samaan

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×